An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia
Status:
Enrolling by invitation
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, open-label multi-center long-term extension study, with approximately 70
subjects, to evaluate the safety and efficacy of BMN111 in children with Achondroplasia until
subjects reach near-adult final height. Eligible subjects will have completed 1 year of
BMN111 or placebo treatment in the 111-206 study and once enrolled in the 111-208 extension
study will receive a daily dose of BMN111 by subcutaneous injection according to their age as
determined by 111-206.